G2Gbio
Public Β· 1 known investors
G2GBIO (Good to the Globe Biotech) is a pharmaceutical company developing improved new drug injectable formulations, with platform technology applicable to treatments for various diseases and mass-production techniques. It focuses on supplying medicines under a "Humanity First" vision.
Also known as G2G Bio Β· G2GBIO Β· G2GBIO Inc. Β· Good to the Globe Biotech Β· μ§ν¬μ§λ°μ΄μ€
Investors Β· 1
Company profile
researched Aug 2026G2GBIO Inc. (μ§ν¬μ§λ°μ΄μ€, also referred to as G2G Bio) is a South Korean pharmaceutical developer of improved long-acting injectable formulations built on sustained-release microsphere technology. The company developed its own InnoLAMP (Innovative Long-Acting MicroParticle) process to overcome limitations of conventional emulsion-based microsphere manufacturing, and a second platform, InteLAMP, in which sustained-release microspheres distributed within tumor tissue release drug intended to kill cancer cells. The platform is presented as applicable across multiple active pharmaceutical ingredients and disease areas, together with cost-competitive mass-production processes.
Development programs described in the sources cover sustained-release treatments for dementia, diabetes and obesity, and postoperative pain. The lead candidate, GB-5001, is a once-monthly formulation of donepezil (marketed as Aricept by Eisai) for Alzheimer's disease; the company has reported Phase 1 multiple-dose safety and tolerability findings and presented repeat-dosing data at the AAIC conference. Other disclosed work includes preclinical data on dual and triple agonists presented at the ADA meeting and a US patent registration for sustained-release semaglutide microspheres.
The company operates an R&D center conducting long-acting formulation, analytical and production-process research, and a GMP-compliant manufacturing facility located inside the KBIO Health building in Osong, Chungcheongbuk-do, capable of producing products for clinical trials and early-stage commercialization, alongside a laboratory with 10-20 kg pilot equipment.
Founding story
G2G Bio was founded in 2017 by Heeyong Lee.
Business model
The company develops improved long-acting injectable formulations of existing drugs using its own microsphere platforms and pursues partnerships and licensing-type collaborations with pharmaceutical companies, supported by internal GMP manufacturing capacity for clinical and early commercial supply.
Revenue is expected from long-acting injectable products and platform-based collaboration with pharmaceutical partners; the sources do not state revenue figures.
Traction
The 2025 Korea Exchange listing raised β©52.2 billion (US$37.7 million), with nearly half earmarked for expanding manufacturing plants to mass-produce sustained-release injectables including GB-5001. Clinical progress includes Phase 1 multiple-dose safety and tolerability results for GB-5001 and first disclosure of once-monthly repeat-dosing data at AAIC; preclinical dual/triple agonist data were presented at ADA and a sustained-release semaglutide microsphere patent was registered in the United States.
Latest developments
In 2026 the company reported Phase 1 multiple-dose safety and tolerability results for GB-5001 (Aug. 27, 2026), signed a memorandum of understanding with Celltrion on ultra-high-concentration subcutaneous antibody technology, agreed a collaboration with SpiderCore applying AI to long-acting injectable development, presented AAIC data on its once-monthly dementia treatment, held around 40 partnering meetings at BIO USA, joined CPHI China 2026, disclosed preclinical dual/triple agonist data at ADA, and obtained US registration of a semaglutide sustained-release microsphere patent (May 19, 2026).
βΈFull profile β market position, technology, go-to-market, geography, history
Market position
A Korea Exchange-listed developer of sustained-release microsphere injectables, positioning its InnoLAMP platform against conventional emulsion-based microsphere manufacturing and targeting long-acting versions of established drugs such as donepezil and semaglutide.
Proprietary InnoLAMP microsphere manufacturing process developed in-house to address limitations of standard emulsion methods, combined with claimed cost-competitive mass-production capability, in-house clinical-grade GMP and pilot-scale facilities, and a platform approach applicable to multiple APIs and indications.
Technology
Two proprietary platforms are described: InnoLAMP (Innovative Long-Acting MicroParticle), an in-house microsphere manufacturing technology developed to overcome the limits of conventional emulsion-based methods and used to produce sustained-release microspheres; and InteLAMP, in which sustained-release microspheres distributed evenly through tumor tissue release drug intended to act selectively on cancer cells. The company also cites price-competitive mass-production technology and platform applicability to therapeutics for a range of diseases, supported by an in-house GMP facility and 10-20 kg pilot-scale equipment.
Go-to-market
Business development is pursued through conference and trade-show presence and partnering meetings, including approximately 40 consecutive partnering meetings at BIO USA, participation in CPHI China 2026, and scientific data presentations at AAIC and ADA. The company also signed technology collaboration agreements with other pharmaceutical and technology firms and holds investor relations events disclosing business status.
Pharmaceutical and biotechnology companies seeking long-acting injectable formulation technology and manufacturing, and ultimately patients treated for Alzheimer's disease/dementia, diabetes and obesity, postoperative pain, and cancer.
Geography
Headquartered in South Korea, with an R&D center and a GMP facility inside the KBIO Health building in Osong, Chungcheongbuk-do; earlier coverage places the company in Daejeon and 2025 coverage in Cheongju-si. Business development activity extends to the United States (BIO USA, US patent registration) and China (CPHI China).
History
Founded in 2017, the company was based in Daejeon, South Korea at the time of its β©11.4 billion (US$9.53 million) Series B round in 2020, which was earmarked for clinical trials of a sustained-release Alzheimer's treatment and nonclinical work in diabetes and sustained-release postoperative pain. It later passed the technical evaluation required for a Korean IPO and listed on the Korea Exchange on Aug. 14, 2025, raising β©52.2 billion (US$37.7 million). Corporate address is given as Cheongju-si, South Korea in 2025 coverage.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 11
launches, deals, and filingsThe company announced confirmation of safety and tolerability in multiple-dose administration in the Phase 1 trial of GB-5001.
Repeat-dosing data for the once-monthly donepezil long-acting candidate GB-5001 were presented at the Alzheimer's Association International Conference.
G2Gbio Inc. debuted on the Korea Exchange on Aug. 14, 2025 with a β©52.2 billion (US$37.7 million) IPO; nearly half of the proceeds were designated for expanding manufacturing plants to mass-produce sustained-release injectables such as GB-5001.
$37.7M source β
The company raised β©11.4 billion (US$9.53 million) in a Series B round, to fund clinical trials of a sustained-release Alzheimer's treatment and nonclinical trials for diabetes and sustained-release postoperative pain treatments.
$9.5M source β
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 8
primary sources listed
- G2Gbiog2gbio.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does G2Gbio do?
- Korean pharmaceutical company developing long-acting microsphere injectables based on its InnoLAMP platform.
- Who are G2Gbio's investors?
- G2Gbio's investors include Atinum Investment Co. Ltd..